Poxel Aktie
0,18EUR | -0,01EUR | -5,68% |
WKN DE: A14M04 / ISIN: FR0012432516
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 0 | 53 | 56 | 37 | 6 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,13 | 0,24 | 0,02 | 0,33 |
Bilanz (in Mio. EUR) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 53 | 46 | 36 | 17 | 5 |
Summe Anlagevermögen | 19 | 19 | 18 | 18 | 0 |
Summe Aktiva | 72 | 65 | 55 | 35 | 5 |
Bilanz (in Mio. EUR) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 11 | 24 | 35 | 44 | 47 |
Summe Fremdkapital | 33 | 38 | 47 | 53 | 54 |
Summe Eigenkapital | 39 | 27 | 8 | -18 | -49 |
Summe Passiva | 72 | 65 | 55 | 35 | 5 |
Adresse
259/261, Avenue Jean Jaurès, 69007 Lyon | |
Telefon | +33 (4) 37-37-20-12 |
Internet | http://www.poxelpharma.com |
Management
Fanny Bosa
Vice President-Finance & Administration |
Mohammed Khoso Baluch
Chairman |
Pascale Boissel
Independent Director |
Quentin Durand
Executive Vice President- Legal Affairs & CSR |
Richard N. Kender
Independent Director |
Sylvie Bertrand
Vice President-Human Resources |
Tejdeep Bawa
Vice President-Business Development |
Thomas Kuhn
Chief Executive Officer & Director |